Takeda Expected to Post Lower First-Quarter Net Profit

Dow Jones07-28

Takeda Pharmaceutical is scheduled to report first-quarter results on Thursday. Here's what you need to know:

NET PROFIT FORECAST: Takeda's first-quarter net profit is estimated to have fallen 31% to 85.3 billion yen, equivalent to $520.9 million, for the three months ended June, according to a poll of analysts by Visible Alpha. The Japanese drugmaker posted net profit of Y124.2 billion in the year-earlier period.

REVENUE FORECAST: Revenue is expected to have risen 4.6% to Y1.157 trillion, according to the Visible Alpha poll.

The stock has gained 19% year to date after rising 16% in 2025.

WHAT TO WATCH:

--For the fiscal year ending March 2027, the company has projected revenue of Y4.640 trillion and net profit of Y166.0 billion. Investors will be focusing on changes to the annual guidance as well as any impact that the Middle East conflict has on its operations.

--Fourth-quarter sales of ulcerative colitis drug Entyvio declined 0.7% to Y213.5 billion while sales of plasma-derived products rose 7.5% to Y267.0 billion. Investors will be closely watching for sales momentum of key products.

--Takeda said in June it booked a provision of Y402.5 billion for antitrust litigation related to constipation drug Amitiza. The company said it intended to pursue post-trial motions and an appeal, in which investors will watch closely for updates.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2654008627?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-28 17:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2654008627","market":"us","top_or_hot":-1,"title":"Takeda Expected to Post Lower First-Quarter Net Profit","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Takeda Pharmaceutical is scheduled to report first-quarter results on Thursday. Here's what you need to know: \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  NET PROFIT FORECAST: Takeda's first-quarter net profit is estimated to have fallen 31% to 85.3 billion yen, equivalent to $520.9 million, for the three months ended June, according to a poll of analysts by Visible Alpha. The Japanese drugmaker posted net profit of Y124.2 billion in the year-earlier period. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  REVENUE FORECAST: Revenue is expected to have risen 4.6% to Y1.157 trillion, according to the Visible Alpha poll. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  The stock has gained 19% year to date after rising 16% in 2025. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  WHAT TO WATCH: \n</p>\n<p>\n  --For the fiscal year ending March 2027, the company has projected revenue of Y4.640 trillion and net profit of Y166.0 billion. Investors will be focusing on changes to the annual guidance as well as any impact that the Middle East conflict has on its operations. \n</p>\n<p>\n  --Fourth-quarter sales of ulcerative colitis drug Entyvio declined 0.7% to Y213.5 billion while sales of plasma-derived products rose 7.5% to Y267.0 billion. Investors will be closely watching for sales momentum of key products. \n</p>\n<p>\n  --Takeda said in June it booked a provision of Y402.5 billion for antitrust litigation related to constipation drug Amitiza. The company said it intended to pursue post-trial motions and an appeal, in which investors will watch closely for updates. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Takeda Expected to Post Lower First-Quarter Net Profit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTakeda Expected to Post Lower First-Quarter Net Profit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-28 17:50</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Takeda Pharmaceutical is scheduled to report first-quarter results on Thursday. Here's what you need to know: \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  NET PROFIT FORECAST: Takeda's first-quarter net profit is estimated to have fallen 31% to 85.3 billion yen, equivalent to $520.9 million, for the three months ended June, according to a poll of analysts by Visible Alpha. The Japanese drugmaker posted net profit of Y124.2 billion in the year-earlier period. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  REVENUE FORECAST: Revenue is expected to have risen 4.6% to Y1.157 trillion, according to the Visible Alpha poll. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  The stock has gained 19% year to date after rising 16% in 2025. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  WHAT TO WATCH: \n</p>\n<p>\n  --For the fiscal year ending March 2027, the company has projected revenue of Y4.640 trillion and net profit of Y166.0 billion. Investors will be focusing on changes to the annual guidance as well as any impact that the Middle East conflict has on its operations. \n</p>\n<p>\n  --Fourth-quarter sales of ulcerative colitis drug Entyvio declined 0.7% to Y213.5 billion while sales of plasma-derived products rose 7.5% to Y267.0 billion. Investors will be closely watching for sales momentum of key products. \n</p>\n<p>\n  --Takeda said in June it booked a provision of Y402.5 billion for antitrust litigation related to constipation drug Amitiza. The company said it intended to pursue post-trial motions and an appeal, in which investors will watch closely for updates. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4212","symbol_name":"包装食品与肉类","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2654008627","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2654008627","pubTimestamp":1785232200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Takeda Pharmaceutical is scheduled to report first-quarter results on Thursday. Here's what you need to know:NET PROFIT FORECAST: Takeda's first-quarter net profit is estimated to have fallen 31% to 8","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4212":"包装食品与肉类","BK4007":"制药","POST":"Post Holdings","TAK":"武田制药"},"translate_title":"武田预计第一季度净利润将下降","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"POST":1.5,"TAK":0.9},"content_text":"Takeda Pharmaceutical is scheduled to report first-quarter results on Thursday. Here's what you need to know: \n\n\n \n\n\n  NET PROFIT FORECAST: Takeda's first-quarter net profit is estimated to have fallen 31% to 85.3 billion yen, equivalent to $520.9 million, for the three months ended June, according to a poll of analysts by Visible Alpha. The Japanese drugmaker posted net profit of Y124.2 billion in the year-earlier period. \n\n\n \n\n\n  REVENUE FORECAST: Revenue is expected to have risen 4.6% to Y1.157 trillion, according to the Visible Alpha poll. \n\n\n \n\n\n  The stock has gained 19% year to date after rising 16% in 2025. \n\n\n \n\n\n  WHAT TO WATCH: \n\n\n  --For the fiscal year ending March 2027, the company has projected revenue of Y4.640 trillion and net profit of Y166.0 billion. Investors will be focusing on changes to the annual guidance as well as any impact that the Middle East conflict has on its operations. \n\n\n  --Fourth-quarter sales of ulcerative colitis drug Entyvio declined 0.7% to Y213.5 billion while sales of plasma-derived products rose 7.5% to Y267.0 billion. Investors will be closely watching for sales momentum of key products. \n\n\n  --Takeda said in June it booked a provision of Y402.5 billion for antitrust litigation related to constipation drug Amitiza. The company said it intended to pursue post-trial motions and an appeal, in which investors will watch closely for updates.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2654008627","isCrawlerRequest":true}